cilostazol has been researched along with Non-alcoholic Fatty Liver Disease in 4 studies
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease linked to insulin resistance, oxidative stress, and cytokine imbalance." | 1.56 | Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. ( Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is an increasingly studied condition that can progress to end-stage liver disease." | 1.48 | Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK. ( Choi, Y; Kim, HY; Kwon, WY; Lee, MH; Lee, SY; Nam, TG; Oh, YJ; Suh, SH; Yoo, YH, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JB | 1 |
| Ko, K | 1 |
| Baek, YH | 1 |
| Kwon, WY | 2 |
| Suh, S | 1 |
| Han, SH | 1 |
| Kim, YH | 1 |
| Kim, HY | 2 |
| Yoo, YH | 2 |
| El-Deen, RM | 1 |
| Heeba, GH | 1 |
| Abdel-Latif, RG | 1 |
| Khalifa, MMA | 1 |
| Oh, YJ | 1 |
| Lee, MH | 1 |
| Suh, SH | 1 |
| Choi, Y | 1 |
| Nam, TG | 1 |
| Lee, SY | 1 |
| Chen, Y | 1 |
| Pandiri, I | 1 |
| Joe, Y | 1 |
| Kim, HJ | 1 |
| Kim, SK | 1 |
| Park, J | 1 |
| Ryu, J | 1 |
| Cho, GJ | 1 |
| Park, JW | 1 |
| Ryter, SW | 1 |
| Chung, HT | 1 |
4 other studies available for cilostazol and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Pharmacological Prevention of Ectopic Erythrophagocytosis by Cilostazol Mitigates Ferroptosis in NASH.
Topics: Animals; Cilostazol; Ferroptosis; Humans; Inflammation; Mice; Non-alcoholic Fatty Liver Disease | 2023 |
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Topics: Animals; Antioxidants; Biomarkers; Cilostazol; Diet, High-Fat; Fatty Liver; Inflammation; Insulin; I | 2020 |
Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cilostazol; Diet, High-Fat; Down-Regulatio | 2018 |
Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Cells, Cultured; Cilostazol; Disease Models | 2016 |